John Tole, DO
Allergy · Birmingham, ALNPI 1568671584
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 23.8%. 2025 is the largest year on record at $11,521, more than ten times the $1,135 reported in 2019.
Across 774 payments — averaging $42.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Consortium Of Independent Immunology Clinics, LLC$8K
- AstraZeneca$6K
- Novartis$4K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$2K
- plus $8K from 30 others
Across 1 payment — averaging $1750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Consortium Of Independent Immunology Clinics, LLC$2K
Across 2 payments — averaging $17,119 each. An ownership or investment interest held by the physician or an immediate family member.
- Consortium Of Independent Immunology Clinics, LLC$34K
What the payments were for
- Consulting fees$10,21231%
- Speaking & faculty fees$3,25010%
- Travel & lodging$1,4554%
- Food & beverage$17,96754%
- Education$2681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Consortium Of Independent Immunology Clinics, LLC | 6 | $7,889 |
| AstraZeneca(2 entities) | 174 | $5,621 |
| Novartis | 28 | $4,007 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $3,865 |
| GSK | 94 | $2,070 |
| Regeneron Healthcare Solutions, Inc. | 60 | $1,569 |
| CSL Behring | 45 | $1,271 |
| Pfizer | 60 | $1,112 |
| Grifols USA, LLC | 51 | $1,070 |
| Genentech USA, Inc. | 47 | $1,017 |
| Sanofi | 25 | $869 |
| Octapharma USA, Inc. | 21 | $507 |
| Teva Pharmaceuticals USA, Inc. | 37 | $378 |
| Pharming Healthcare, Inc. | 9 | $291 |
| ADMA Biomanufacturing LLC | 3 | $235 |
| Amgen | 13 | $233 |
| Blueprint Medicines Corporation | 9 | $195 |
| Biocryst US Sales Co., LLC | 8 | $153 |
| Kaleo, Inc. | 8 | $121 |
| Galderma Laboratories, L.p. | 1 | $93 |
| LEO Pharma Inc. | 5 | $87 |
| GC Biopharma USA, Inc. | 4 | $87 |
| Hikma Pharmaceuticals USA | 3 | $56 |
| Shire North American Group Inc | 3 | $50 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $50 |
| Cycle Pharmaceuticals Inc | 2 | $47 |
| Boehringer Ingelheim | 3 | $43 |
| Alk-abello, Inc | 2 | $35 |
| Ionis Pharmaceuticals, Inc. | 1 | $22 |
| Kedrion Biopharma, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $18 |
| Organon | 1 | $17 |
| Merck | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Optinose US, Inc. | 1 | $14 |
| Tersera Therapeutics LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $232,877 |
| Dupixent SyringeDupilumab | 47 | $172,957 |
| NucalaMepolizumab | 43 | $156,688 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $137,452 |
| Dupixent PenDupilumab | 25 | $94,060 |
| XolairOmalizumab | 25 | $90,891 |
| TezspireTezepelumab-Ekko | 21 | $86,362 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $72,281 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 107 | $71,893 |
| ZemairaAlpha-1-Proteinase Inhibitor | 47 | $48,858 |
| DuleraMometasone/Formoterol | 60 | $19,779 |
| SymbicortBudesonide/Formoterol Fumarate | 83 | $18,630 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $14,680 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $12,665 |
| Epinephrine | 40 | $11,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $2,070 | $246,433186 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $3,865 | $232,87712 claims |
| CSL BehringHizentra, Zemaira | $1,271 | $186,31064 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $5,621 | $176,884211 claims |
| MerckDulera | $16 | $19,77960 claims |
| Hikma Pharmaceuticals USAEpinephrine | $56 | $11,47840 claims |
| Boehringer IngelheimSpiriva Respimat | $43 | $11,10920 claims |
| Teva Pharmaceuticals USA, Inc.Proair Respiclick | $378 | $88113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Alabamaon file to place this against a meaningful peer group, so we don't.
Other allergy in Birmingham
- John MeadowsBirmingham$204K
- William FancherBirmingham$3K
- Joseph GiannobileBirmingham$991
- Druhan HowellMobile$201K
- Shashi KumarHuntsville$8K
- Lucinda PattonMobile$3K
- Valerie leMadison$1K
- Charles BrentnallSylacauga$1K
- Steven HelmTuscaloosa$185
- Alma HerreraMobile$19
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.